Donor-derived Hematopoietic Tissue
Donor-derived Hematopoietic Tissue - Related Videos
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
0 Views •
Cited by 2 •
2017
Quantification of donor-derived cells is required to monitor engraftment after stem cell transplantation in patients with hemoglobinopathies. A combination of flow cytometry-based cell sorting, colony formation assay, and subsequent analysis of short tandem repeats may be used to assess the proliferation and differentiation of progenitors in the erythroid compartment.
22:06
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
0 Views •
Cited by 7 •
2007
This protocol details the derivation of transplantable hematopoietic stem cells from mouse embryonic stem cells (ESC) and their subsequent injection into lethally irradiated recipient mice. Briefly, ESC are differentiated as embryoid bodies, which are then infected with retroviral HoxB4 and co-cultured with OP9 stromal cells and hematopoietic cytokines.
05:18
Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors
0 Views •
Cited by 5 •
2017
The leptomeninges explant culture protocol from human postmortem brain is a technically robust and simple way to derive fibronectin-positive meningeal fibroblasts within 6-8 weeks and cryopreserve approximately 20-30 million cells.
08:37
Corneal Donor Tissue Preparation for Endothelial Keratoplasty
0 Views •
Cited by 31 •
2012
Endothelial corneal transplantation is a surgical technique for treatment of posterior corneal diseases. Mechanical microkeratome dissection to prepare tissue results in thinner, more symmetric grafts with less endothelial cell loss and improved outcomes. Dissections can be performed at the eye bank prior to corneal transplantation surgery.
08:53
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
0 Views •
Cited by 16 •
2016
This protocol provides step-by-step guidelines for setting up competitive mouse bone marrow transplant experiments to study hematopoietic stem/progenitor cell function without prior purification of stem cells by cell sorting.
FAQs
Human leukocyte antigen (HLA) compatibility is a central determinant of how donor and recipient immune systems interact. Greater compatibility can support acceptance of the transplanted hematopoietic cells, whereas disparities may intensify immune complications. For this reason, HLA matching is assessed during donor selection and interpreted alongside conditioning, cell dose, and clinical risk.
Conditioning treatment is one of the variables that shapes whether donor-derived hematopoietic tissue can successfully restore hematopoiesis. It is considered together with HLA compatibility and the number of transplanted cells when clinicians plan treatment. Because conditioning also contributes to the recipient’s overall risk profile, its effects must be weighed against complications such as infection and graft failure.
The number of hematopoietic stem and progenitor cells delivered can influence transplantation success. Cell dose is therefore evaluated as a distinct planning factor rather than treated as interchangeable with HLA compatibility. Together, dose and donor-recipient immune relationships affect the likelihood that the graft will home to marrow and generate blood and immune cells.
Donor-recipient immune interactions can produce both successful reconstitution and clinically important complications. The same immunologic relationship involved in replacing the recipient’s blood-forming system may also contribute to graft-versus-host disease. Monitoring these interactions is essential because immune effects are not captured by cell dose or HLA matching alone.
Clinical planning begins by identifying an appropriate donor and evaluating the available hematopoietic source: bone marrow, peripheral blood, or umbilical cord blood. The selected product is then considered in relation to HLA compatibility, conditioning treatment, cell dose, and immune risk. This integrated assessment helps clinicians choose a transplant strategy rather than relying on source type alone.
It is used in settings where the recipient’s hematopoietic system must be replaced or restored, including leukemia, lymphoma, aplastic anemia, and inherited blood diseases. These conditions differ clinically, but they share a need for renewed blood-forming and immune-cell production. The approach is therefore relevant across malignant, marrow-failure, and inherited hematologic disorders rather than limited to one diagnosis.
Follow-up evaluates whether donor-derived hematopoietic tissue has restored blood and immune-cell production without major complications. Clinicians monitor for graft-versus-host disease, infection, graft failure, and other adverse outcomes identified during care. These observations help determine whether hematopoietic recovery is proceeding as intended and whether immune or graft-related problems require attention.